I have not written anything about the disease, but as the same and all the fallout that leaves become very painful, it seemed appropriate to report this fairly new drug in Spain.
As you will read who arrive here, this treatment s not unique to this disease, is a pain treatment with opioids, improving the untenable situation that I personally, cause these opioids, the terrible constipation, which sometimes make you go to the hospital to you "unblock", thereby losing the poor quality of life you have left. (I solve one thing, but you spoil other)
I look forward to try it, since my current medication were Fendivia patches of 25 micro-grams (there reached the 75 micro-grams, but I did what I explained above, so I was leaving the treatment, resulting in pain and no recovery without going through the undesirable feeling of the monkey.
I did not create this place to talk about my problem, I mean, not accustomed to talking about what affect me, as I'm going going, if income tomorrow, if I had surgery yesterday .. . Sometimes if I wrote something about me, and if it is a summary of what my life was in hospital revenue and operations, not updated it for years, and that there are no new things, there are only sequelae, which increase, which makes life a daily death, well, who knows just what happens. I go once in a while around here, but if you have any questions about something that you can help, leave it in comments, but I appreciate it dejaseis return address, because if you do not know where to answer, perhaps not answer the comment left, it would depend on the question, opinion, or question left to answer in the comment.
Another day will come to explain things, because I have not taken things that do not work and other issues that have nothing to do with the syndrome.
Here I leave on the drug found in the very journal published by the English Society of Pain.
Silvia
Journal of the English Society of Pain
printed version ISSN 1134
-8046 Rev. Soc Espv.16 n.4 Narón Pain (La Coruña) May 2009
LETTER TO THE EDITOR
Targino ® receives European approval to control severe chronic pain
European Approval of Targino ® for the control of intense pain Chronic
This innovative medication to control severe chronic pain and to prevent intestinal dysfunction induced by combining opioids action oxycodone and naloxone.
Chronic pain affects 1 in every 10 people in our country.
Madrid, April 27, 2009. Mundipharma Pharmaceutical Company has announced the approval of the innovative European ® Targino analgesic indicated for the treatment of severe chronic pain. The new drug, which has received European approval through a decentralized registration procedure in which Spain participated, to control severe chronic pain while reducing significantly the risk of opioid-induced constipation 1-3.
The approval of this drug is based on an extensive clinical development program conducted in several European countries including Spain, which has shown that Targino ® the first dose provides the same relief painkiller oxycodone extended release, reducing significantly the risk of opioid-induced constipation. Targino ® is an oral combination of extended-release oxycodone, an opioid agonist and naloxone increased extended-release opioid antagonist 1-3.
Opioids are the most potent analgesics to control osteoarticular pain and cancer origin, but their use is associated with the onset of gastrointestinal disorders whose main symptom is constipation 4. It affects up to 90% of patients treated with opioids 5 and impacts on their quality of life 6 , which can lead to abandonment of treatment adherence and compromise in patients in need of effective analgesia 7 .
"Targino ® is the first of its kind analgesic specifically designed to provide pain control without compromising intestinal function. Targino ® combines a high analgesic efficacy and tolerability profile that only contributes to enhance the quality of life of patients suffering from severe chronic pain, "says Dr Karen Reimer, European Director of Mundipharma Research and Development.
According to Alberto Martínez, Director General of Mundipharma in Spain, "with the launch of Targino ® (expected in 2010), Mundipharma available to both patients and health professionals that promotes an innovative treatment a qualitative leap in the treatment of chronic pain in Spain. Chronic pain affects 1 in 10 people 8 in our country and hope that Targino ® allows, for the first time that patients do not give up their quality of life to achieve effective control of their pain. "
Targino About ®
Targino tablets ® combine oxycodone, an opioid analgesic greater, and naloxone, an opioid receptor antagonist in a sustained-release oral formulation.
Targino ® has been clinically proven to provide effective analgesic comparable to that of oxycodone, whilst significantly counteracts the opioid-induced constipation, a class effect common to them all.
This drug is already marketed in some European countries.
About Mundipharma Mundipharma
, Purdue and Napp independent associated companies are present in all major global pharmaceutical markets, researching and working to provide patients and health professionals new therapeutic options in pain management, respiratory diseases and oncohematologic. For more information, visit: www.mundipharma.co.uk .
For more information, contact:
Medical Director Susana Traseira
Mundipharma Pharmaceuticals Ltd. Tel: 91 382 April 27
Fax: 91 382 18 71
E-mail: susana.traseira @ mundipharma.es
Mundipharma Pharmaceuticals Ltd. Tel: 91 382 April 27
Fax: 91 382 18 71
E-mail: susana.traseira @ mundipharma.es
Bibliography
1. Vondráčková D, Leyendecker P, Hopp M Meissner W, Szombati I, Hermanns K, et al. Analgesic Efficacy and safety of oxycodone in combination with naloxone as prolonged release tablets in patients with moderate to severe chronic pain. J Pain. 2008;9:1144-54. [ Links ]
2. Meissner W, Leyendecker P, Müller-Lissner S, et al. A randomised controlled trial with prolonged-release oral oxycodone and naloxone to prevent and reverse opioid-induced constipation. Eur J Pain. 2008; doi: 10.1016/j.ejpain.2008.06.012. [ Links ]
3. Simpson K, Leyendecker P, Hopp M, Müller-Lissner S, Löwenstein O, De Andrés J, et al. Fixed-ratio combination oxycodone/ naloxone compared with oxycodone alone for the relief of opioid-induced constipation in moderate-to-severe non-cancer pain. Curr Med Res Opin. 2008;24:3503-12. [ Links ]
4. Bell TJ, Panchal SJ, Miaskowski C, Bolge SC, Milanova T, Williamson R. The prevalence, severity and impact of opioid-induced bowel dysfunction: Results of a US and European patient survey (PROBE 1). Pain Medicine. 2008;10:35-42. [ Links ]
5. Yuan CS, Pappagallo M. Opioid bowel dysfunction. En: Yuan CS, editor. Handbook of opioid bowel syndrome. New York: Haworth Medical Press; 2005. [ Links ]
6. Panchal SJ, Müller-Schwefe P, Wurzelmann JI. Opioid-induced bowel dysfunction: prevalence, pathophysiology and burden. Int J Clin Pract. 2007;61:1181-7. [ Links ]
7. Thorpe DM. Management of opioid-induced constipation. Curr Pain Headache Rep. 2001;5:237-40. [ Links ]
8. Breivik H, Collett B, Ventafridda V, Cohen R, Gallacher D. Survey of chronic pain in Europe: prevalence, impact on daily life and treatment. Eur J Pain. 2006;10:287-333. [ Links ]
© 2011 Elsevier España, S.L.
Travessera de Gràcia, 17-21
08021 - Barcelona
Tlf.: 932 000 711
Fax: 932 091 136
resed@elsevier.com
Travessera de Gràcia, 17-21
08021 - Barcelona
Tlf.: 932 000 711
Fax: 932 091 136
resed@elsevier.com
src="http://pagead2.googlesyndication.com/pagead/show_ads.js"> 
